FDA Proposes Consolidating Manufacturing Information In Applications
Executive Summary
Combining manufacturing establishment information (MEI) in one electronic form as part of new drug submissions could make review more straightforward and efficient, US agency says.
You may also be interested in...
FDA Guidance Clarifies Facility Requirements
The US FDA has made a renewed effort to clarify the types of manufacturing facilities that need to be listed on the Form FDA 356h and Module 3 of the CTD in submissions. Often reviewers find this information missing, which can result in a refuse to file action.
US FDA Details Facilities That NDAs, ANDAs Should Note
The US FDA has made a renewed effort to clarify the types of manufacturing facilities that need to be listed on the Form FDA 356h and Module 3 of the CTD in submissions. Often reviewers find this information missing, whicn can result in a refuse to file action.
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”